Close Menu


A majority of Osmetech's shareholders voted in favor of the plan to float in the US, change the firm's name, and relocate its headquarters to California.

The British molecular diagnostics firm intends to raise around $40 million in a US IPO and will be based in the US as a wholly-owned subsidiary of GenMark Diagnostics.

BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.

Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited takeover bids.

The Canadian firm, which already floats on the Toronto Stock Exchange, is gearing up for the launch of its LungExpress Dx product in the US.

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.

Speaking after the firm's presentation Monday at the UBS Global Life Sciences Conference, Fluidigm CFO Vikram Jog told GenomeWeb Daily News that the company still intends to go public, but the timing remains uncertain.

The funding will support PacBio's effort to launch its SMRT sequencing system in the second half of 2010, and will also serve as a financial "buffer" as the company looks to pursue an initial public offering or other large-scale financing effort some time next year.


According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.

An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.

US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.

In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.